File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Improvement of Overall Survival in Patients with Brain Metastasis. An Analysis of 2003 and 2010 Cohort in a Community Oncology Center

TitleImprovement of Overall Survival in Patients with Brain Metastasis. An Analysis of 2003 and 2010 Cohort in a Community Oncology Center
Authors
Issue Date2012
PublisherOxford University Press. The Journal's web site is located at http://neuro-oncology.dukejournals.org
Citation
European Association of Neuro-oncology Tenth Meeting (EANO 2012 ), 2012. In Neuro-Oncology, 2012, v. 14 n. suppl_3, P.242 How to Cite?
AbstractBACKGROUND: Emerging systemic anticancer treatments and focal CNS treatments for brain metastases (radiosurgery or surgical excision) had been shown in clinical trials to improve the survival of patients with metastatic malignancy. The extent of improvement of survival of patients with brain metastasis in community setting remained uncertain. METHODS: Consecutive patients with diagnosis of brain metastasis in the year 2003 (n = 106) and the year 2010 (n = 107) were retrospectively reviewed. CNS involvement by hematological malignancies were excluded. Univariate and multivariate analyses of prognostic factors were performed. RESULTS: Mean age of the 2003 and the 2010 cohort was 66.3 and 61.2 respectively (p = 0.004). For both of the cohorts, lung primary accounts for about 70% of cases. The patient cohort in 2010 more frequently received focal treatment for brain metastases than 2003 cohort - 18.7% vs 5.7%, (p = 0.003). Systemic treatments, including chemotherapy, hormonal therapy and targeted therapy, were more frequently given in the 2010 cohort (25.2% vs 4.7%, p < 0.0001). Median overall survival of the 2010 cohort was modestly improved by about 1 month compared with the 2003 cohort (92 days vs 63 days, p = 0.003). Improvement was mainly achieved in patients with Karnofsky Performance Status (KPS) ≥70 that 1-year survival increased from 7.2% to 31.3% (p = 0.03). In multivariate analysis, focal CNS treatment (p = 0.002), systemic treatment (p = <0.0001) and KPS ≥70 (p < 0.0001) were independent predictors of overall survival. CONCLUSIONS: Contemporary patients with brain metastasis managed in individualized basis with multidisciplinary input resulted in improvement of overall survival, especially in patients with good performance status.
Descriptionposter award
Persistent Identifierhttp://hdl.handle.net/10722/257548
ISSN
2017 Impact Factor: 9.384
2015 SCImago Journal Rankings: 3.196

 

DC FieldValueLanguage
dc.contributor.authorLam, TC-
dc.contributor.authorWong, F-
dc.contributor.authorSze, W-
dc.contributor.authorTung, S-
dc.date.accessioned2018-08-07T08:24:03Z-
dc.date.available2018-08-07T08:24:03Z-
dc.date.issued2012-
dc.identifier.citationEuropean Association of Neuro-oncology Tenth Meeting (EANO 2012 ), 2012. In Neuro-Oncology, 2012, v. 14 n. suppl_3, P.242-
dc.identifier.issn1522-8517-
dc.identifier.urihttp://hdl.handle.net/10722/257548-
dc.descriptionposter award-
dc.description.abstractBACKGROUND: Emerging systemic anticancer treatments and focal CNS treatments for brain metastases (radiosurgery or surgical excision) had been shown in clinical trials to improve the survival of patients with metastatic malignancy. The extent of improvement of survival of patients with brain metastasis in community setting remained uncertain. METHODS: Consecutive patients with diagnosis of brain metastasis in the year 2003 (n = 106) and the year 2010 (n = 107) were retrospectively reviewed. CNS involvement by hematological malignancies were excluded. Univariate and multivariate analyses of prognostic factors were performed. RESULTS: Mean age of the 2003 and the 2010 cohort was 66.3 and 61.2 respectively (p = 0.004). For both of the cohorts, lung primary accounts for about 70% of cases. The patient cohort in 2010 more frequently received focal treatment for brain metastases than 2003 cohort - 18.7% vs 5.7%, (p = 0.003). Systemic treatments, including chemotherapy, hormonal therapy and targeted therapy, were more frequently given in the 2010 cohort (25.2% vs 4.7%, p < 0.0001). Median overall survival of the 2010 cohort was modestly improved by about 1 month compared with the 2003 cohort (92 days vs 63 days, p = 0.003). Improvement was mainly achieved in patients with Karnofsky Performance Status (KPS) ≥70 that 1-year survival increased from 7.2% to 31.3% (p = 0.03). In multivariate analysis, focal CNS treatment (p = 0.002), systemic treatment (p = <0.0001) and KPS ≥70 (p < 0.0001) were independent predictors of overall survival. CONCLUSIONS: Contemporary patients with brain metastasis managed in individualized basis with multidisciplinary input resulted in improvement of overall survival, especially in patients with good performance status.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://neuro-oncology.dukejournals.org-
dc.relation.ispartofNeuro-Oncology-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.titleImprovement of Overall Survival in Patients with Brain Metastasis. An Analysis of 2003 and 2010 Cohort in a Community Oncology Center-
dc.typeConference_Paper-
dc.identifier.emailLam, TC: lamtc03@hku.hk-
dc.identifier.authorityLam, TC=rp02128-
dc.identifier.doi10.1093/neuonc/nos183-
dc.identifier.hkuros272311-
dc.identifier.volume14-
dc.identifier.issuesuppl_3-
dc.identifier.spageP.242-
dc.identifier.epageP.242-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats